GLP-1 Drugs Against Gambling Addiction: Wharton School Launches New MRI Study

The medical world is eagerly watching a new field of research that extends far beyond mere weight loss. GLP-1 receptor agonists, known globally under brand names like Ozempic or Wegovy, could play a key role in combating behavioral addictions. Pathological gambling, in particular, is the focus of scientists. At the Wharton School of the University of Pennsylvania, researchers are currently investigating whether these drugs can structurally remodel the brain so that risky financial decisions occur less frequently. It concerns the fundamental question of whether a simple injection can help resist temptations such as excessive luxury consumption or the urge to gamble.

Neuroscientists assume that the body's reward system underlies all consumption decisions. If this system is dampened by GLP-1 preparations, not only might the appetite for food decrease, but also the hunger for quick money at the gaming table or in speculative investments. Research stands at a threshold that could fundamentally change the understanding of self-control and biological programming. Michael Platt, a professor at the Wharton School, sees an opportunity for the average person to develop better financial habits through a more stable neural basis.

Numbers and facts

The Wharton School research project is designed for a participant count of approximately 180 people. The observation period started in mid-October and is scheduled to run until around March 2027 at the University of Pennsylvania's MindCORE research lab. The relevance of such studies is supported by current data: A 2026 study by Northwestern Mutual found that 73 percent of U.S. citizens view speculative activities like sports betting or cryptocurrencies as a more effective way to build wealth than classic index funds.

The methodical execution of the new study is highly complex. Participants must complete four tasks while their brain activity is monitored using magnetic resonance imaging (MRI). Among other things, 14 images of products and services are shown, including the Powerball jackpot, to measure spontaneous neural reactions without a direct call to action. Interestingly, the distinction is made between necessary purchases and purely enjoyment-oriented rewards.

Background

The history of GLP-1 drugs goes back further than many suspect. As early as 2005, exenatide was approved as the first drug in this class, originally derived from the saliva of the Gila monster. Carolina Haass-Koffler from Brown University emphasizes that these hormones, such as insulin, ghrelin, or leptin, deeply intervene in the control of dopamine and motivation.

"GLP-1s aren’t just targeting the brain, like many older medications. They work more holistically, helping the brain and the body. We’re not just talking about a promising treatment; we’re looking at a potential turning point in addiction psychiatry and public health." - Carolina Haass-Koffler, Associate Professor of Psychiatry at Brown University

This holistic effect could weaken the reward signal in the prefrontal cortex and the nucleus accumbens to the point where the urge for immediate gratification becomes manageable. In MRI tests, subjects must decide whether they would rather take 20 dollars immediately or wait two months for 50 dollars. Those who choose the higher amount demonstrate better impulse control, which may be biologically supported by GLP-1.

Why it matters for German players

In Germany, player protection is strictly regulated by the State Treaty on Gambling 2021 (GlüStV 2021). Mechanisms such as the cross-provider deposit limit of 1,000 euros per month and the central blocking system LUGAS serve to prevent excessive gambling behavior at an early stage. Nevertheless, individual impulse control remains a critical factor. Should the results of the Wharton study be confirmed, drug-based approaches could become a supplementary pillar in addiction therapy for German players in the future. Currently, however, the use of GLP-1 preparations to treat gambling addiction is purely off-label and is not approved as a standard therapy in Germany. German players currently benefit primarily from the legal stake limits of 1 euro per spin on virtual slot machines, which are intended to limit the risk of rapid, high losses.

What it means for GGL-licensed casinos

Operators with a license from the Gemeinsame Glücksspielbehörde der Länder (GGL) are obliged to implement early detection systems for gambling-addictive behavior. The scientific realization that biochemical processes in the brain are largely responsible for risk perception could refine the development of these algorithms. While casinos in jurisdictions like Curacao or Malta often place less focus on profound player protection, German providers must ensure that vulnerable individuals are consistently identified. Should medical support reduce relapse rates among blocked players, this would relieve the entire system of player protection in Germany. However, it remains to be seen how authorities will integrate such medical progress into their prevention concepts.